• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Top 10 Trending Penny Stocks for Friday, Feb. 4, 2022 (Sentiment via Swaggy Stocks)

    2/4/22 3:52:05 PM ET
    $AGTC
    $CTXR
    $GTE
    $OP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGTC alert in real time by email
    • SOC Telamed (TLMD)
    • Exela Technologies (XELA)
    • Senseonics (SENS)
    • Applied Genetic Technologies (AGTC)
    • Reed's (REED)
    • Citius Pharmaceuticals (CTXR)
    • OceanPal (OP)
    • Exicure (XCUR)
    • Veru (VERU)
    • Gran Tierra Energy (GTE)
    https://swaggystocks.com/dashboard/stocks/hot-penny-stocks-list
    Get the next $AGTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGTC
    $CTXR
    $GTE
    $OP

    CompanyDatePrice TargetRatingAnalyst
    Gran Tierra Energy Inc.
    $GTE
    1/30/2026Buy → Hold
    Canaccord Genuity
    Veru Inc.
    $VERU
    12/18/2025$25.00Buy
    Canaccord Genuity
    Gran Tierra Energy Inc.
    $GTE
    12/12/2025$5.45Buy
    Roth Capital
    Senseonics Holdings Inc.
    $SENS
    10/21/2025$9.00Hold
    Stifel
    Senseonics Holdings Inc.
    $SENS
    8/27/2025$1.50Overweight
    Barclays
    Senseonics Holdings Inc.
    $SENS
    7/15/2025$1.25Buy
    TD Cowen
    Gran Tierra Energy Inc.
    $GTE
    6/20/2025Mkt Perform
    Raymond James
    Senseonics Holdings Inc.
    $SENS
    6/2/2025$1.10Buy
    H.C. Wainwright
    More analyst ratings

    $AGTC
    $CTXR
    $GTE
    $OP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ENTADFI issued to VERU INC

    Submission status for VERU INC's drug ENTADFI (ORIG-1) with active ingredient FINASTERIDE;TADALAFIL has changed to 'Approval' on 12/09/2021. Application Category: NDA, Application Number: 215423, Application Classification: Type 4 - New Combination

    12/13/21 8:12:46 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGTC
    $CTXR
    $GTE
    $OP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Roeder Douglas A bought $100,275 worth of shares (17,500 units at $5.73), increasing direct ownership by 17% to 119,731 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    3/16/26 10:44:45 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    President and CEO Goodnow Timothy T bought $99,733 worth of shares (17,225 units at $5.79), increasing direct ownership by 3% to 651,243 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    3/16/26 10:44:00 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Large owner Lm Asset Management Inc. bought $604,558 worth of shares (94,000 units at $6.43) (SEC Form 4)

    4 - GRAN TIERRA ENERGY INC. (0001273441) (Issuer)

    3/4/26 5:40:25 PM ET
    $GTE
    Oil & Gas Production
    Energy

    $AGTC
    $CTXR
    $GTE
    $OP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value

    Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, March 27, 2026 /CNW/ -- Equity-Insider.com News Commentary – The traditional hospital model is undergoing a massive structural shift. Outpatient clinics and ambulatory services are quickly becoming the primary growth engines for the entire U.S. healthcare sector. In fact, Ernst & Young's 2026 outlook confirms that these accessible, lower-acuity care segments are attracting the heaviest strategic capital allocations as health systems realign their infrastructure[1]. This powerful momentum is accelerating across the medical technology space. Recent data from NVIDIA's 2026 healthcare survey shows that 70% of organizations are now ac

    3/27/26 10:15:00 AM ET
    $CLOV
    $LIVN
    $MBOT
    Medical Specialities
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Biotechnology: Biological Products (No Diagnostic Substances)

    Exicure, Inc. Reports Full Year 2025 Financial Results

    REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position: Cash and cash equivalents were $3.7 million as of December 31, 2025, compared to $12.5 million as of December 31, 2024. Our current liquidity may not be sufficient to fund operations for the next 12 months. Additional financing will be required to support ongoing operations, continue the exploration of strategic alternatives, and pursue any alternatives that we identify. Research and Development (R&D) Expense: Research and development expenses were $3.3 million for the ye

    3/25/26 4:18:31 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Reed's Reports Fourth Quarter and Full Year 2025 Results; Announces Leadership Transition

    Profitable Growth Initiatives Lead to Sequential Quarterly Improvement  Neal Cohane Appointed Interim Chief Executive Officer NORWALK, Conn., March 24, 2026 (GLOBE NEWSWIRE) -- Reed's, Inc. (NYSE:REED) ("Reed's" or the "Company"), owner of the nation's leading portfolio of handcrafted, natural ginger beverages, today announced financial results for the three months and 12 months ended December 31, 2025. Additionally, the Company announced that Neal Cohane has been appointed to serve as interim Chief Executive Officer and member of the board of directors, effective today. Former CEO and Board Member Cyril Wallace has stepped down. The board has begun conducting a search for a permanent CE

    3/24/26 4:05:00 PM ET
    $REED

    $AGTC
    $CTXR
    $GTE
    $OP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Gran Tierra Energy downgraded by Canaccord Genuity

    Canaccord Genuity downgraded Gran Tierra Energy from Buy to Hold

    1/30/26 6:58:54 AM ET
    $GTE
    Oil & Gas Production
    Energy

    Canaccord Genuity initiated coverage on Veru with a new price target

    Canaccord Genuity initiated coverage of Veru with a rating of Buy and set a new price target of $25.00

    12/18/25 9:11:57 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Gran Tierra Energy with a new price target

    Roth Capital initiated coverage of Gran Tierra Energy with a rating of Buy and set a new price target of $5.45

    12/12/25 8:50:39 AM ET
    $GTE
    Oil & Gas Production
    Energy

    $AGTC
    $CTXR
    $GTE
    $OP
    SEC Filings

    View All

    SEC Form 8-K filed by Reed's Inc.

    8-K - REED'S, INC. (0001140215) (Filer)

    4/17/26 4:05:25 PM ET
    $REED

    SEC Form EFFECT filed by Veru Inc.

    EFFECT - VERU INC. (0000863894) (Filer)

    4/16/26 12:15:18 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Veru Inc.

    EFFECT - VERU INC. (0000863894) (Filer)

    4/16/26 12:15:17 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGTC
    $CTXR
    $GTE
    $OP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Ellson Ryan

    4/A - GRAN TIERRA ENERGY INC. (0001273441) (Issuer)

    4/14/26 4:51:25 PM ET
    $GTE
    Oil & Gas Production
    Energy

    Amendment: SEC Form 4 filed by Abraham Phillip D

    4/A - GRAN TIERRA ENERGY INC. (0001273441) (Issuer)

    4/14/26 4:50:40 PM ET
    $GTE
    Oil & Gas Production
    Energy

    Amendment: SEC Form 4 filed by Guidry Gary

    4/A - GRAN TIERRA ENERGY INC. (0001273441) (Issuer)

    4/14/26 4:49:32 PM ET
    $GTE
    Oil & Gas Production
    Energy

    $AGTC
    $CTXR
    $GTE
    $OP
    Leadership Updates

    Live Leadership Updates

    View All

    Reed's, Inc. Announces Appointment of Neal Cohane as Chief Operating Officer

    NORWALK, Conn., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reed's, Inc. (NYSE:REED) ("Reed's" or the "Company"), owner of the nation's leading portfolio of handcrafted, natural ginger beverages, today announced the appointment of Neal Cohane as Chief Operating Officer, effective January 5, 2026. Mr. Cohane brings decades of leadership experience across the beverage industry and a proven track record of building high-performing commercial organizations, scaling national distribution, and driving sustainable growth for consumer brands. Most recently, he served as Chief Sales Officer at Eastroc Beverages and previously founded Rootstock Brands, Inc., where he advised beverage companies on go-to-mar

    12/29/25 4:30:00 PM ET
    $REED

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Gran Tierra Energy Inc. Appoints New Director

    CALGARY, Alberta, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Gran Tierra Energy Inc. ("Gran Tierra" or the "Company") (NYSE:GTE)(TSX:GTE)(LSE:GTE) is pleased to announce the appointment of Brad Virbitsky to the Company's Board of Directors as an independent director, effective September 30, 2025. Mr. Virbitsky is a portfolio manager and partner at Equinox Partners LLC, a Connecticut-based investment firm with over 30 years of history in natural resources and emerging markets. Mr. Virbitsky has over a decade of experience working with management teams and boards to advise on long-term corporate and financial strategies. He has developed deep expertise in the global energy sector and has traveled e

    9/30/25 11:10:47 PM ET
    $GTE
    Oil & Gas Production
    Energy

    $AGTC
    $CTXR
    $GTE
    $OP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Reeds Inc.

    SC 13D/A - REED'S, INC. (0001140215) (Subject)

    12/6/24 4:30:32 PM ET
    $REED

    Amendment: SEC Form SC 13D/A filed by Reeds Inc.

    SC 13D/A - REED'S, INC. (0001140215) (Subject)

    12/4/24 6:11:30 AM ET
    $REED

    Amendment: SEC Form SC 13D/A filed by Exela Technologies Inc.

    SC 13D/A - Exela Technologies, Inc. (0001620179) (Subject)

    12/3/24 4:01:40 PM ET
    $XELA
    Business Services
    Consumer Discretionary

    $AGTC
    $CTXR
    $GTE
    $OP
    Financials

    Live finance-specific insights

    View All

    Exicure, Inc. Reports Full Year 2025 Financial Results

    REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position: Cash and cash equivalents were $3.7 million as of December 31, 2025, compared to $12.5 million as of December 31, 2024. Our current liquidity may not be sufficient to fund operations for the next 12 months. Additional financing will be required to support ongoing operations, continue the exploration of strategic alternatives, and pursue any alternatives that we identify. Research and Development (R&D) Expense: Research and development expenses were $3.3 million for the ye

    3/25/26 4:18:31 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Reed's Reports Fourth Quarter and Full Year 2025 Results; Announces Leadership Transition

    Profitable Growth Initiatives Lead to Sequential Quarterly Improvement  Neal Cohane Appointed Interim Chief Executive Officer NORWALK, Conn., March 24, 2026 (GLOBE NEWSWIRE) -- Reed's, Inc. (NYSE:REED) ("Reed's" or the "Company"), owner of the nation's leading portfolio of handcrafted, natural ginger beverages, today announced financial results for the three months and 12 months ended December 31, 2025. Additionally, the Company announced that Neal Cohane has been appointed to serve as interim Chief Executive Officer and member of the board of directors, effective today. Former CEO and Board Member Cyril Wallace has stepped down. The board has begun conducting a search for a permanent CE

    3/24/26 4:05:00 PM ET
    $REED

    Reed's Schedules Fourth Quarter & Full Year 2025 Conference Call for March 25 at 8:30 a.m. ET

    NORWALK, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- Reed's, Inc. (NYSE:REED) ("Reed's" or the "Company"), owner of the nation's leading portfolio of handcrafted, natural ginger beverages, will host a conference call on Wednesday, March 25, 2026, at 8:30 a.m. Eastern time to discuss its financial results for the three and twelve months ended December 31, 2025. The Company's results will be reported in a press release prior to the call. Reed's management will host the conference call, followed by a question-and-answer period. Date: Wednesday, March 25, 2026Time: 8:30 a.m. Eastern timeToll-free dial-in number: (800) 717-1738International dial-in number: (646) 307-1865Conference ID: 59633Webc

    3/11/26 4:30:00 PM ET
    $REED